These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8383388)

  • 1. Inactivated hepatitis A vaccine in childhood: implications for disease control.
    Nalin D; Brown L; Kuter B; Patterson C; McGuire B; Werzberger A; Santosham M; Block S; Reisinger K; Watson B
    Vaccine; 1993; 11 Suppl 1():S15-7. PubMed ID: 8383388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis.
    Shouval D; Ashur Y; Adler R; Lewis JA; Armstrong ME; Davide JP; McGuire B; Kuter B; Brown L; Miller W
    Vaccine; 1993; 11 Suppl 1():S9-14. PubMed ID: 8383390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL
    Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous passive and active immunization against hepatitis A.
    Leentvaar-Kuijpers A; Coutinho RA; Brulein V; Safary A
    Vaccine; 1992; 10 Suppl 1():S138-41. PubMed ID: 1335646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of inactivated hepatitis A vaccine in children.
    Lee SD; Lo KJ; Chan CY; Yu MY; Wang YJ; Safary A
    Gastroenterology; 1993 Apr; 104(4):1129-32. PubMed ID: 8462802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine.
    Dagan R; Greenberg D; Goldenbertg-Gehtman P; Vidor E; Briantais P; Pinsk V; Athias O; Dumas R
    Vaccine; 1999 Apr; 17(15-16):1919-25. PubMed ID: 10217590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of vaccine-induced antibody to hepatitis A virus.
    Wiedermann G; Ambrosch F; André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S129-31. PubMed ID: 1335643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults.
    Reuman PD; Kubilis P; Hurni W; Brown L; Nalin D
    Vaccine; 1997 Jul; 15(10):1157-61. PubMed ID: 9269062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
    Davidson M; Krugman S; Sandman LA
    Vaccine; 1992; 10 Suppl 1():S119-20. PubMed ID: 1335639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity.
    Van Damme P; Matheï C; Thoelen S; Meheus A; Safary A; André FE
    J Med Virol; 1994 Dec; 44(4):435-41. PubMed ID: 7897376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with an inactivated hepatitis A vaccine.
    Clemens R; Safary A; Hepburn A; Roche C; Stanbury WJ; André FE
    J Infect Dis; 1995 Mar; 171 Suppl 1():S44-9. PubMed ID: 7876648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A.
    Delem A; Safary A; De Namur F; Hauser P; D'Hondt E
    Vaccine; 1993; 11(4):479-84. PubMed ID: 8385844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis A vaccination: schedule for accelerated immunization.
    Müller R; Chriske H; Deinhardt F; Jilg J; Theilmann L; Hess G; Hofmann F; Hopf U; Stickl H; Maiwald H
    Vaccine; 1992; 10 Suppl 1():S124-5. PubMed ID: 1335641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children.
    Balcarek KB; Bagley MR; Pass RF; Schiff ER; Krause DS
    J Infect Dis; 1995 Mar; 171 Suppl 1():S70-2. PubMed ID: 7876652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatitis A vaccination schedules on immune response.
    Tilzey AJ; Palmer SJ; Barrow S; Perry KR; Tyrell H; Safary A; Banatvala JE
    Vaccine; 1992; 10 Suppl 1():S121-3. PubMed ID: 1335640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.
    André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.
    Nalin DR; Kuter BJ; Brown L; Patterson C; Calandra GB; Werzberger A; Shouval D; Ellerbeck E; Block SL; Bishop R
    J Hepatol; 1993; 18 Suppl 2():S51-5. PubMed ID: 8182275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.
    Newcomer W; Rivin B; Reid R; Moulton LH; Wolff M; Croll J; Johnson C; Brown L; Nalin D; Santosham M
    Pediatr Infect Dis J; 1994 Jul; 13(7):640-2. PubMed ID: 7970954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.
    Werzberger A; Mensch B; Kuter B; Brown L; Lewis J; Sitrin R; Miller W; Shouval D; Wiens B; Calandra G
    N Engl J Med; 1992 Aug; 327(7):453-7. PubMed ID: 1320740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.